Resonance Health Limited ASX: RHT Annual General Meeting 24 th - - PowerPoint PPT Presentation

▶
resonance health limited
SMART_READER_LITE
LIVE PREVIEW

Resonance Health Limited ASX: RHT Annual General Meeting 24 th - - PowerPoint PPT Presentation

Oct 31, 2022 227 likes •393 views

ASX: RHT Resonance Health Limited ASX: RHT Annual General Meeting 24 th November 2016 Disclaimer ___________________________________________________________________________________________ This presentation contains forward looking statements

slide-1
SLIDE 1

Resonance Health Limited

ASX: RHT Annual General Meeting 24th November 2016

ASX: RHT

slide-2
SLIDE 2

Disclaimer

___________________________________________________________________________________________

This presentation contains forward looking statements which may be subject to significant uncertainties outside of the Company’s control. No representation is made as to the accuracy or reliability of forward looking statements or the assumptions on which they are based. Actual future events may vary from these forward looking statements and you are cautioned not to place undue reliance on any forward looking statement.

slide-3
SLIDE 3

Resonance Health Limited

___________________________________________________________________________________________

  • RHT develops and delivers non-invasive

quantitative medical imaging software and services

  • Market capitalisation ~ AU$10M

(approx. 400 million shares on issue)

  • Significant investment in marketing, R&D

and team

  • Net loss reported of $384k for FY 2015/16
  • Cash on hand at 30 September of $2.0M
slide-4
SLIDE 4

Year in Review: Growth and Development

___________________________________________________________________________________________

FerriScan

Grow established markets

  • Record clinical image analyses
  • 25 new sites

Develop new markets

  • Sickle Cell: 25% sales increase USA
  • Cancer survivors

HepaFat-Scan

Generate data & publications

  • 8 studies with KOLs & paper published

Diversify (liver and other organs systems)

Fibrosis test prototype

  • Investigate commercial readiness

Bone marrow iron

  • Progress to commercial product 2017

Pancreatic fat

  • New investigational product (diabetes)

Spleen volume

  • New investigational product (clinical trial)

Value-add (combination products)

FerriScan + HepaFat-Scan

  • Hyperferritinaemia & Cancer survivors

HepaFat-Scan + Pancreatic fat

  • Metabolic syndrome / Diabetes T2
slide-5
SLIDE 5

2015 2016 2017 2018 2019

UK UK

AUS

UK AUS

Year in Review: HepaFat-Scan Studies

___________________________________________________________________________________________

Malaysia USA

USA

UK

UK UK Malaysia AUS USA AUS

Paediatric NAFLD Unexplained Hyperferritinaemia Diabetes (x2) Surgery (x2) Population Health Studies (x2)

slide-6
SLIDE 6

Strategy

_______________________________________________________________________________________________

  • Grow

established and new markets

  • Sickle cell
  • Cancer

survivors

  • Collaborative

programs

  • Combined use
  • f FS & HFS

1

FerriScan & HepaFat- Scan

  • Evaluate

potential new CPT code submission

  • German

reimbursement

  • Italian

reimbursement

2

  • Efficiencies

and further automation of established products

  • New

applications

  • New

collaborations

3

New Advances

  • Broaden

product portfolio

  • Bone marrow

iron

  • Pancreatic fat
  • Spleen

volume

  • Inflammation /

fibrosis

4

Reimbursement Diversify

slide-7
SLIDE 7

The Liver and Beyond

_______________________________________________________________________________________________

  • Expertise in the liver
  • ther organ systems
  • Heart, Bone Marrow, Spleen and Pancreas
  • HepaFat-Scan + Pancreatic fat
  • Fatty Liver, Diabetes, Metabolic Syndrome

NAFLD / NASH Obesity epidemic (developed countries):

  • 20 – 30% have NAFLD
  • 2 - 3% at risk of

inflammation (NASH) & fibrosis At risk of NASH USA: ~10 M China & India: ~50 M Diabetes Type II Worldwide: ~380 M

slide-8
SLIDE 8

FerriScan: Strategy

_______________________________________________________________________________________________

Develop new markets 1) Sickle Cell Disease (USA – 100k patients)

– 15% patients receive regular blood transfusions – Evidence shows benefit of FerriScan – Guidelines in place

2) Cancer Survivors (USA – 350k paediatrics)

– 5 – 10% receive > 10 blood transfusions – Marketing campaign launched – Long term follow-up centres – Iron overload audit with key sites

“Cancer survivors with excess iron may be exposed to this iron for years ahead if untreated, so timely monitoring and reduction of iron burden is an important goal1”

1) Dr Angela Smith, Assistant Professor, Division of Pediatric Blood and Marrow Transplantation at the University of Minnesota

slide-9
SLIDE 9

HepaFat-Scan: Strategy

___________________________________________________________________________________________

  • KOLs using in 8 active studies

– Generate evidence to enhance uptake – 2 studies near completion

  • Pharma trials

Combination with FerriScan

  • Cancer Survivors

– Transfusions Iron overload – Chemotherapy Fatty liver

  • Unexplained Hyperferritinaemia

– Raised serum ferritin level – Is it caused by iron overload or fatty liver?

Combination with Pancreatic Fat

  • Metabolic Syndrome / Diabetes
slide-10
SLIDE 10

Reimbursement: Strategy

_______________________________________________________________________________________________

  • FerriScan currently reimbursed in:

– UK (NHS trusts) – Canada (MOH Ontario) – US (selected payers) – Germany (case-by-case)

1) USA

  • Obtain advice around renewed CPT application

2) Germany

– Finalising reimbursement application

3) Italy

  • Lobbying government through KOL advocacy
slide-11
SLIDE 11

New Advances: Strategy

_______________________________________________________________________________________________

  • Advances in Computer Science (Machine Learning)

– Develop new low cost LIC measurement product – Opens large volume markets, e.g. developing countries – Application in established RH technology (efficiencies)

  • Potential for new products/partnerships
  • Collaborations

– Other imaging diagnostic companies – Radiology partners – Research partners – Pharma companies

slide-12
SLIDE 12

Diversify: Strategy

_______________________________________________________________________________________________

New investigational products

  • Bone marrow iron assessment

– 50k+ transplants pa regulatory filing

  • Pancreatic fat assessment (Diabetes)
  • Organ volume measurements
  • Standardised assessment of biopsy

R&D

  • Non-invasive measurement of

– Liver inflammation – Liver fibrosis

  • Proof-of-concept
  • Application: NAFLD, NASH
slide-13
SLIDE 13

Product Status Summary

_______________________________________________________________________________________________

Research Proof of Concept Validation Regulatory Clearance

On Market

Reim- bursement FerriScan UK / Can Cardiac T2* HepaFat-Scan Bone Marrow Iron Pancreatic Fat Fibrosis Inflammation Machine Learning Can

slide-14
SLIDE 14

Summary: 2017 Focus

_______________________________________________________________________________________________

  • Investing in growth and diversification
  • New markets for established products

– Sickle cell disease – Cancer survivors – Unexplained hyperferritinaemia

  • FerriScan & HepaFat-Scan combination
  • Revisiting reimbursement

– CPT code USA – New: Germany and Italy

  • Expansion of product pipeline

– Bone marrow iron regulatory submission – Pancreatic fat (metabolic syndrome/diabetes) – Potential low cost LIC measurement

slide-15
SLIDE 15

ASX: RHT

www.resonancehealth.com